We previously showed that the immune system not only protects individuals against tumor outgrowth but also facilitates tumor escape by sculpting tumor cell immunogenicity, a process we called “Cancer Immunoediting”. We subsequently elucidated the mechanisms underlying cancer immunoediting, demonstrated the importance of tumor-specific mutant neoantigens as targets of this process, and translated our findings into cancer immunotherapies by showing that tumor-specific mutant neoantigens can be used to generate therapeutically effective personalized cancer vaccines against established tumors. We have since gone on to define the minimal antigenic requirements for therapeutically effective personalized cancer vaccines and documented the synergistic activity that neoantigen vaccines show when used in combination with current immunotherapies, chemotherapies and radiotherapy. Most recently we have developed evidence for a powerful immunodominance effect that occurs between different tumor antigens and have identified what appears to be a unique mechanism by which at least some forms of immunotherapies induce tumor specific destruction. These findings will be discussed.
Citation Format: Robert D. Schreiber. Personalizing cancer immunotherapy. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2016 Oct 20-23; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2017;5(3 Suppl):Abstract nr IA23.